DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Toralizumab
Toralizumab
Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
(12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis Et Al
B Cell Checkpoints in Autoimmune Rheumatic Diseases
Modifications to the Harmonized Tariff Schedule of the United States To
The Two Tontti Tudiul Lui Hi Ha Unit
I Regulations
Anti-CD154 [IDEC-131 (Toralizumab)] Bulk Size Ab01678- 10.0-BT
INN Working Document 05.179 Update 2011
New Targets in Systemic Lupus (Part 2/2)ଝ Walter A
Emerging Therapies in Immune Thrombocytopenia
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Rationale for CD40 Pathway Blockade in Autoimmune Rheumatic Disorders Pucino, Valentina; Gardner, David; Fisher, Benjamin
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
(2) Patent Application Publication (10) Pub. No.: US 2013/0251671 A1 Kaufman Et Al
Top View
University of Birmingham Rationale for CD40 Pathway Blockade In
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Wo 2010/095940 A2
Targeting the CD40-CD40L Pathway in Autoimmune Diseases: Humoral Immunity and Beyond
Customs Tariff - Schedule Xxi - 1
Anti-CD154 [IDEC-131 (Toralizumab)] Standard Size Ab01678-3.0
1 New Therapies for Systemic Lupus Erythematosus — Past Imperfect
WO 2014/140862 A2 18 September 2014 (18.09.2014) P O P C T
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
(INN) for Biological and Biotechnological Substances
Thalidomide - Wikipedia, the Free Encyclopedia
B-Cell Targeted Therapeutics in Clinical Development
WO 2013/120629 Al 22 August 2013 (22.08.2013) P O P C T
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Combinations of an Anti-HER2 Antibody-Drug Conjugate and Docetaxel